# Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

> **NCT07016724** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 208 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** cadonilizumab combined with neoadjuvant radiochemotherapy
- **COMBINATION_PRODUCT:** neoadjuvant radiochemotherapy

## Key facts

- **NCT ID:** NCT07016724
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2025-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07016724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07016724, "Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07016724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*